Literature DB >> 24970113

Uptake and repeat use of postexposure prophylaxis in a community-based clinic in Los Angeles, California.

Matthew R Beymer1, Robert K Bolan, Risa P Flynn, Dustin R Kerrone, David L Pieribone, Sonali P Kulkarni, Jackelyn C Stitt, Everardo Mejia, Raphael J Landovitz.   

Abstract

Postexposure prophylaxis (PEP) has become an important tool for HIV prevention in the men who have sex with men (MSM) communities within Los Angeles County. However, it is unclear as to whether the most sexually at-risk MSM populations are accessing PEP services. Furthermore, it is unclear what behavioral risk factors differentiate individuals who utilize PEP once (single PEP) versus those who utilize it multiple times (re-PEP). Data were collected between May 2011 and December 2012 on all clients enrolled in the Los Angeles LGBT Center's (the Center) PEP-LA program as well as on all sexually transmitted infection (STI) screening clients visiting the Center. Multivariate logistic regression models were used to analyze results. PEP clients had greater odds of having a history of gonorrhea in the past year when compared to high-risk, non-PEP clients (OR: 1.71; CI: 1.25-2.35). Furthermore, they had greater odds of using methamphetamines (OR: 1.71; CI: 1.30-2.24) and inhaled nitrates (OR: 1.62; CI: 1.30-2.01) in the past 12 months when compared to high-risk, non-PEP clients. Re-PEP clients had greater odds of methamphetamine use than single PEP clients (OR: 2.80; CI: 1.65-4.75). There were no significant differences by race/ethnicity between high-risk, non-PEP clients and PEP clients in either the entire cohort or MSM only sample. However, African Americans made up 8.5% of persons accessing PEP services but 16.7% of persons who tested HIV positive. Similar proportions of PEP use by race/ethnicity are problematic considering the disproportionate burden of HIV infections in the African American community. Although uptake among the highest risk populations has been brisk (n=649), inequities based upon race/ethnicity suggest the need for increased outreach.

Entities:  

Mesh:

Year:  2014        PMID: 24970113      PMCID: PMC4151052          DOI: 10.1089/AID.2014.0017

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  25 in total

1.  Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.

Authors:  Dawn K Smith; Lisa A Grohskopf; Roberta J Black; Judith D Auerbach; Fulvia Veronese; Kimberly A Struble; Laura Cheever; Michael Johnson; Lynn A Paxton; Ida M Onorato; Alan E Greenberg
Journal:  MMWR Recomm Rep       Date:  2005-01-21

2.  Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States.

Authors:  Susan P Buchbinder; Eric Vittinghoff; Patrick J Heagerty; Connie L Celum; George R Seage; Franklyn N Judson; David McKirnan; Kenneth H Mayer; Beryl A Koblin
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

3.  Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes.

Authors:  Anne Laporte; Nathalie Jourdan; Elisabeth Bouvet; Franck Lamontagne; Josiane Pillonel; Jean-Claude Desenclos
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

4.  Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco.

Authors:  Kate Buchacz; Willi McFarland; Timothy A Kellogg; Lisa Loeb; Scott D Holmberg; James Dilley; Jeffrey D Klausner
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

Review 5.  Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus.

Authors:  Peter L Havens
Journal:  Pediatrics       Date:  2003-06       Impact factor: 7.124

6.  Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers.

Authors:  D C Scheid; R M Hamm; K W Stevens
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

7.  Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis.

Authors:  Isaac I Bogoch; Eileen P Scully; Kimon C Zachary; Sigal Yawetz; Kenneth H Mayer; Chaim M Bell; Jason R Andrews
Journal:  Clin Infect Dis       Date:  2014-04-10       Impact factor: 9.079

8.  Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.

Authors:  David T Kuhar; David K Henderson; Kimberly A Struble; Walid Heneine; Vasavi Thomas; Laura W Cheever; Ahmed Gomaa; Adelisa L Panlilio
Journal:  Infect Control Hosp Epidemiol       Date:  2013-09       Impact factor: 3.254

9.  Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.

Authors:  Steven D Pinkerton; Jeffrey N Martin; Michelle E Roland; Mitchell H Katz; Thomas J Coates; James O Kahn
Journal:  Arch Intern Med       Date:  2004-01-12

10.  Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.

Authors:  Mauro Schechter; Regina F do Lago; Aaron B Mendelsohn; Ronaldo I Moreira; Lawrence H Moulton; Lee H Harrison
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

View more
  4 in total

1.  Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.

Authors:  Liza Dawson; Sam Garner; Chuka Anude; Paul Ndebele; Shelly Karuna; Renee Holt; Gail Broder; Jessica Handibode; Scott M Hammer; Magdalena E Sobieszczyk
Journal:  Clin Trials       Date:  2015-04-07       Impact factor: 2.486

2.  Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California.

Authors:  Matthew R Beymer; Robert E Weiss; Robert K Bolan; Ryan M Kofron; Risa P Flynn; David L Pieribone; Sonali P Kulkarni; Raphael J Landovitz
Journal:  Open Forum Infect Dis       Date:  2017-04-04       Impact factor: 3.835

3.  Trends in HIV post-exposure prophylaxis following sexual exposure in Brazil (2011-2019).

Authors:  Kennedy Crepalde-Ribeiro; Juliana de Oliveira Costa; Sallie-Anne Pearson; Micheline Rosa Silveira; Jullye Campos Mendes; Simone Furtado Dos Santos; Márcio Afonso Cruz; Maria das Graças Braga
Journal:  AIDS Behav       Date:  2022-07-16

4.  Sexual Identity Disclosure and Awareness of HIV Prevention Methods Among Black Men Who Have Sex With Men.

Authors:  Ryan J Watson; Jessica N Fish; Aerielle Allen; Lisa Eaton
Journal:  J Sex Res       Date:  2017-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.